Compare KYN & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYN | IMNM |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | KYN | IMNM |
|---|---|---|
| Price | $14.35 | $19.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 344.2K | ★ 1.1M |
| Earning Date | 01-01-0001 | 03-03-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | $20.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.82 | $5.15 |
| 52 Week High | $14.49 | $27.65 |
| Indicator | KYN | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 36.87 |
| Support Level | $12.09 | $19.26 |
| Resistance Level | $14.45 | $22.57 |
| Average True Range (ATR) | 0.25 | 1.05 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 79.86 | 1.41 |
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.